ER Positive Breast Cancer: 247 Real Stories

247 stories match breast cancer and ER positive. 215 of them mention surgery.

Cancer Stories

Genoa, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Amelia, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient Story
OutcomeCare Ongoing
Cat, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient Story
OutcomeCancer-Free / NED
Bethany, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient Story
OutcomeCare Ongoing
Tina, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient Story
OutcomeCare Ongoing
Natalie, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 HR-Positive Invasive Ductal Carcinoma: Natalie's Survivor Story

Patient Info: Natalie, Female | Stage 0

Biomarkers: ER-positive

As of June 2026, Natalie was living after Stage 0 DCIS, later nipple/Paget's disease recurrence, and 20 surgeries through May 2019, with a full life and ongoing attention to physical changes after reconstruction.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Amy, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Amy’s Stage 4 Hormone-Positive Lobular Breast Cancer Story

Patient Info: Amy, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: Spine; pelvis

Amy was living with de novo stage 4 lobular breast cancer involving the spine and pelvis and remained active in rural-patient advocacy.

Lobular Breast Cancer Alliance
OutcomeLiving With Cancer / Ongoing Therapy
SI
Breast Cancer

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER-positive/HER2-positive breast cancer with rare paranasal sinus and skull metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and paranasal sinus metastasis were ER positive, PR negative, HER2 positive; GATA3 supported breast origin in metastasis.

Metastatic Site: left frontal sinus; ethmoid air cells; posterior…

The paranasal sinus/skull metastasis did not respond to palliative radiotherapy; her condition deteriorated and she died 2 years after her initial presentation to the treating facility.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed Central
OutcomeResponding Well
Janet, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of Hope
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Discovered After Widespread Bone Metastases

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER 90–95%; PR 90–95%; HER2 IHC 0; Ki-67 5%; germline BRCA1/2 negative

Metastatic Site: bone, bone marrow

She was receiving ongoing letrozole and ribociclib for Stage IV hormone receptor-positive, HER2-negative breast cancer with diffuse bone involvement.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage 2 breast cancer: lump discovered at 61, successful treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Breast neuroendocrine tumor was ER/PR strongly positive, HER2 1+

Metastatic Site: lung, mediastinal lymph nodes, bone (ribs, spine,…

After Stage IIA primary breast neuroendocrine tumor treated with lumpectomy, sentinel lymph-node biopsy, radiation, and short-duration anastrozole, the patient developed metastatic recurrence about 2 years later, declined additional therapy, entered hospice, and died 1 month later.

PubMed Central
OutcomeIn Memory
Erica, who was diagnosed with Stage I Invasive Lobular CarcinomaBreast Cancer

Stage I HR-Positive Invasive Lobular Carcinoma: Erica's Survivor Story

Patient Info: Erica, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2025, Erica had Stage IA ER-positive/PR-positive/HER2-negative ILC removed with negative lymph nodes, completed 16 rounds of radiation, and was focused on survivorship and advocacy.

Lobular Breast Cancer Alliance
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV ER/PR-positive breast cancer with retinal vein and artery occlusion during endocrine-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 70%; PR 100%; HER2-negative; Ki-67 10%

Metastatic Site: bone (cranial vault, right first rib, sternum, D5, D6,…

As of November 2025, she continued care for Stage IV ER/PR-positive breast cancer with bone metastases while also managing severe left-eye retinal vascular occlusion and limited visual recovery.

PubMed Central
OutcomeCare Ongoing
Janella, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed Central
OutcomeCancer-Free / NED